Literature DB >> 28204917

[ECG score to predict ICD therapies in patients with nonischemic cardiomyopathy and primary prophylactic CRT-D].

Martin Grett1, Martin Christ2, Jan-Peter Röing Gen Nölke2, Hans-Joachim Trappe2.   

Abstract

BACKGROUND AND PROBLEM: Recently published results of the DANISH study raise concerns, if primary prophylactic ICD implantations in patients with nonischemic cardiomyopathy (NICM) and severe reduced left ventricular ejection fraction (LVEF) should be performed without further risk stratification. There was no significant difference in the overall mortality of patients with or without ICD and CRT defibrillator (CRT-D) or CRT pacemaker (CRT-P), respectively. Clinical risk scores to identify patients with ischemic cardiomyopathy (ICM) who benefit most from an ICD have been recommended. The need for risk stratification systems concerning patients with NICM has been emphasized. STUDY DESIGN AND METHODS: A retrospective study of 434 consecutive patients with CRT-D implantation was performed. Patients with no regular follow-up at our institution (n = 132), secondary prophylactic ICD indication (n = 61), and upgrade to CRT (n = 95) were excluded. The occurrence of an adequate ICD therapy was defined as the endpoint. Left ventricular ejection fraction (LVEF), genesis of the cardiomyopathy as well as the modified Selvester ECG score (MSES) for evaluation of the left ventricular scar burden were documented among other characteristics.
RESULTS: Within a median follow-up of 605 days, 24% of the patients experienced an adequate ICD therapy. These patients had significantly lower LVEF (20% vs. 23%), and the MSES was higher (7 vs. 3 points). There was no significant difference in patients suffering from ICM vs NICM. A receiver-operating-characteristic (ROC) analysis revealed a sensitivity of 0.914 and a specifity of 0.586 for MSES ≥4 to predict the occurrence of an ICD therapy. None of 35 patients suffering from NICM with MSES <4 experienced an ICD therapy.
INTERPRETATION: The evaluation of the left ventricular scar burden using MSES can be useful for the decision between CRT-D and CRT-P in patients suffering from NICM.

Entities:  

Keywords:  Cardiac resynchronization therapy; ECG score; Implantable cardioverter-defibrillator; Nonischemic cardiomyopathy; Risk stratification

Mesh:

Year:  2017        PMID: 28204917     DOI: 10.1007/s00399-017-0490-6

Source DB:  PubMed          Journal:  Herzschrittmacherther Elektrophysiol        ISSN: 0938-7412


  15 in total

1.  The extent of left ventricular scar quantified by late gadolinium enhancement MRI is associated with spontaneous ventricular arrhythmias in patients with coronary artery disease and implantable cardioverter-defibrillators.

Authors:  Paul A Scott; John M Morgan; Nicola Carroll; David C Murday; Paul R Roberts; Charles R Peebles; Stephen P Harden; Nick P Curzen
Journal:  Circ Arrhythm Electrophysiol       Date:  2011-04-14

2.  Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.

Authors:  Gust H Bardy; Kerry L Lee; Daniel B Mark; Jeanne E Poole; Douglas L Packer; Robin Boineau; Michael Domanski; Charles Troutman; Jill Anderson; George Johnson; Steven E McNulty; Nancy Clapp-Channing; Linda D Davidson-Ray; Elizabeth S Fraulo; Daniel P Fishbein; Richard M Luceri; John H Ip
Journal:  N Engl J Med       Date:  2005-01-20       Impact factor: 91.245

3.  Reverse remodeling and the risk of ventricular tachyarrhythmias in the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy).

Authors:  Alon Barsheshet; Paul J Wang; Arthur J Moss; Scott D Solomon; Amin Al-Ahmad; Scott McNitt; Elyse Foster; David T Huang; Helmut U Klein; Wojciech Zareba; Michael Eldar; Ilan Goldenberg
Journal:  J Am Coll Cardiol       Date:  2011-06-14       Impact factor: 24.094

4.  A standardized definition of ischemic cardiomyopathy for use in clinical research.

Authors:  G Michael Felker; Linda K Shaw; Christopher M O'Connor
Journal:  J Am Coll Cardiol       Date:  2002-01-16       Impact factor: 24.094

5.  Myocardial fibrosis predicts appropriate device therapy in patients with implantable cardioverter-defibrillators for primary prevention of sudden cardiac death.

Authors:  Leah Iles; Heinz Pfluger; Lisa Lefkovits; Michelle J Butler; Peter M Kistler; David M Kaye; Andrew J Taylor
Journal:  J Am Coll Cardiol       Date:  2011-02-15       Impact factor: 24.094

6.  A detailed guide for quantification of myocardial scar with the Selvester QRS score in the presence of electrocardiogram confounders.

Authors:  Zak Loring; Sreetharan Chelliah; Ronald H Selvester; Galen Wagner; David G Strauss
Journal:  J Electrocardiol       Date:  2011 Sep-Oct       Impact factor: 1.438

7.  Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure.

Authors:  Lars Køber; Jens J Thune; Jens C Nielsen; Jens Haarbo; Lars Videbæk; Eva Korup; Gunnar Jensen; Per Hildebrandt; Flemming H Steffensen; Niels E Bruun; Hans Eiskjær; Axel Brandes; Anna M Thøgersen; Finn Gustafsson; Kenneth Egstrup; Regitze Videbæk; Christian Hassager; Jesper H Svendsen; Dan E Høfsten; Christian Torp-Pedersen; Steen Pehrson
Journal:  N Engl J Med       Date:  2016-08-27       Impact factor: 91.245

8.  Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy.

Authors:  Alan Kadish; Alan Dyer; James P Daubert; Rebecca Quigg; N A Mark Estes; Kelley P Anderson; Hugh Calkins; David Hoch; Jeffrey Goldberger; Alaa Shalaby; William E Sanders; Andi Schaechter; Joseph H Levine
Journal:  N Engl J Med       Date:  2004-05-20       Impact factor: 91.245

Review 9.  The need to modify patient selection to improve the benefits of implantable cardioverter-defibrillator for primary prevention of sudden death in non-ischaemic dilated cardiomyopathy.

Authors:  Marcello Disertori; Silvia Quintarelli; Silvia Mazzola; Valentina Favalli; Nupoor Narula; Eloisa Arbustini
Journal:  Europace       Date:  2013-08-14       Impact factor: 5.214

10.  Complications after cardiac implantable electronic device implantations: an analysis of a complete, nationwide cohort in Denmark.

Authors:  Rikke Esberg Kirkfeldt; Jens Brock Johansen; Ellen Aagaard Nohr; Ole Dan Jørgensen; Jens Cosedis Nielsen
Journal:  Eur Heart J       Date:  2013-12-17       Impact factor: 29.983

View more
  1 in total

1.  Cardioverter-defibrillator does not improve short-term survival among patients with non-ischemic cardiomyopathy and reduced left ventricular ejection fraction.

Authors:  Clemens Jilek; Thorsten Lewalter; Matthias Pauschinger; Wolfgang von Scheidt; Lutz Frankenstein; Otmar Pfister; Rainer Hambrecht; Oliver Bruder; Johannes Brachmann; Andreas Hartmann; Ruth Strasser; Matthias Hochadel; Jochen Senges
Journal:  Clin Res Cardiol       Date:  2019-06-24       Impact factor: 5.460

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.